Hyperactivity Disorder Stocks List

Recent Signals

Date Stock Signal Type
2021-04-09 ALKS 200 DMA Support Bullish
2021-04-09 ALKS Bollinger Band Squeeze Range Contraction
2021-04-09 ALKS MACD Bullish Signal Line Cross Bullish
2021-04-09 COLL Pocket Pivot Bullish Swing Setup
2021-04-09 COLL Spinning Top Other
2021-04-09 DRRX Narrow Range Bar Range Contraction
2021-04-09 LLY MACD Bullish Signal Line Cross Bullish
2021-04-09 SUPN Narrow Range Bar Range Contraction
2021-04-09 SUPN Non-ADX 1,2,3,4 Bullish Bullish Swing Setup
2021-04-09 SUPN Calm After Storm Range Contraction
2021-04-09 SUPN NR7 Range Contraction
2021-04-09 SUPN 50 DMA Support Bullish
2021-04-09 SUPN NR7-2 Range Contraction

Recent News for Hyperactivity Disorder Stocks

Date Stock Title
Apr 12 ITCI Intra-Cellular Therapies Presents Data on Antitumor Effects of Phosphodiesterase I Inhibition in a Preclinical Colorectal Cancer Model at the 2021 American Association for Cancer Research (AACR) Annual Meeting
Apr 12 LLY Wall Street Breakfast: Alibaba Relief
Apr 12 LLY Lilly's retevmo shows antitumor activity in solid tumors
Apr 11 LLY Lilly Presents New Data on Retevmo® (selpercatinib) in Advanced RET Fusion-Positive Gastrointestinal and Other Cancers at 2021 American Association for Cancer Research (AACR) Annual Meeting
Apr 10 LLY The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
Apr 10 LLY Which Stock Is Likely to Be the Biggest Winner: Lilly, Vir, or GlaxoSmithKline?
Apr 9 LLY Top Stock Reports for Oracle, Eli Lilly & BP
Apr 9 LLY Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study
Apr 9 LLY Pharma Stock Roundup: FDA Decision Delays for PFE, LLY, ABBV, AZN Vaccine Woes
Apr 9 LLY NIH recommends Lilly and Regeneron's combination antibody treatments to people with mild and moderate COVID-19
Apr 9 LLY Provention Bio Shares Crash 40% Due To Regulatory Setback For Diabetes Drug
Apr 9 LLY The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Apr 9 LLY Provention Bio Stock Craters After FDA Flags Deficiencies In PK Profiles From Teplizumab Trials For Diabetes
Apr 8 LLY Lilly woes provide buying opportunity, Danaher a buy with likely earnings beat, and more in today's analyst action
Apr 8 ALKS Alkermes (ALKS) Inks Deal With Merck for Ovarian Cancer Study
Apr 8 LLY Eli Lilly-Incyte's Baricitinib Study In Hospitalized COVID-19 Patients Fails To Meet Main Goal
Apr 8 LLY Lilly, Incyte's COV-BARRIER study fails to meet primary endpoint in COVID-19
Apr 8 LLY Eli Lilly and Incyte say Phase 3 study of baricitinib in hospitalized COVID-19 patients failed to meet main goal
Apr 8 LLY Lilly and Incyte announce results from the Phase 3 COV-BARRIER study of baricitinib in hospitalized COVID-19 patients
Apr 7 ALKS Alkermes and Merck team up for late-stage ovarian cancer study

Attention deficit hyperactivity disorder (ADHD) is a mental disorder of the neurodevelopmental type. It is characterized by difficulty paying attention, excessive activity, or difficulty controlling behavior which is not appropriate for a person's age. The symptoms appear before a person is twelve years old, are present for more than six months, and may cause problems in at least two settings (such as school, home, or recreational activities). In children, problems paying attention may result in poor school performance. Additionally there is an association with other mental disorders and substance misuse. Although it causes impairment, particularly in modern society, many people with ADHD can have sustained attention span for tasks they find interesting or rewarding (known as hyperfocus).Despite being the most commonly studied and diagnosed mental disorder in children and adolescents, the exact cause is unknown in the majority of cases. It affects about 5–7% of children when diagnosed via the DSM-IV criteria and 1–2% when diagnosed via the ICD-10 criteria. As of 2015 it is estimated to affect about 51.1 million people globally. Rates are similar between countries and depend mostly on how it is diagnosed. ADHD is diagnosed approximately two times more often in boys than in girls, although the disorder is often overlooked in girls because their symptoms differ from those of boys. About 30–50% of people diagnosed in childhood continue to have symptoms into adulthood and between 2–5% of adults have the condition. In adults inner restlessness rather than hyperactivity may occur. The condition can be difficult to tell apart from other conditions, as well as to distinguish from high levels of activity that are still within the range of normative behaviors.ADHD management recommendations vary by country and usually involve some combination of counseling, lifestyle changes, and medications. The British guideline only recommends medications as a first-line treatment in children who have severe symptoms and for medication to be considered in those with moderate symptoms who either refuse or fail to improve with counseling, though for adults medications are a first-line treatment. Canadian and American guidelines recommend that medications and behavioral therapy be used together as a first-line therapy, except in preschool-aged children. Stimulant medication therapy is not recommended as a first-line therapy in preschool-aged children in either guideline. Treatment with stimulants is effective for at least 14 months; however, their long term effectiveness is unclear. Adults often develop coping skills which make up for some or all of their impairments.The medical literature has described symptoms similar to those of ADHD since the 18th century. ADHD, its diagnosis, and its treatment have been considered controversial since the 1970s. The controversies have involved clinicians, teachers, policymakers, parents, and the media. Topics include ADHD's causes and the use of stimulant medications in its treatment. Most healthcare providers accept ADHD as a genuine disorder in children and adults, and the debate in the scientific community mainly centers on how it is diagnosed and treated. The condition was officially known as attention-deficit disorder (ADD) from 1980 to 1987, while before this it was known as hyperkinetic reaction of childhood.

More about Hyperactivity Disorder
Browse All Tags